Epidemiology
British Journal of Cancer (2002) 87, 61–64. doi:10.1038/sj.bjc.6600350 www.bjcancer.com
Published online 25 June 2002
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study
T Bjørge1,2, A Engeland3, T Luostarinen4, J Mork5,6, R E Gislefoss7, E Jellum7, P Koskela8, M Lehtinen8, E Pukkala4, SØ Thoresen5 and J Dillner9
- 1Department of Pathology, The Norwegian Radium Hospital, 0310 Oslo, Norway
- 2Department of Gynecologic Oncology, The Norwegian Radium Hospital, 0310 Oslo, Norway
- 3Division of Epidemiology, Norwegian Institute of Public Health, 0403 Oslo, Norway
- 4Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, 00170 Helsinki, Finland
- 5Cancer Registry of Norway, Institute of Population-based Cancer Research, 0310 Oslo, Norway
- 6Department of Oto-rhino-laryngology, The National Hospital, 0027 Oslo, Norway
- 7Janus Committee, Norwegian Cancer Society, 0369 Oslo, Norway
- 8National Public Health Institute, 00300 Helsinki and Oulu, Finland
- 9Department of Medical Microbiology, Lund University, MAS University Hospital, S-20502 Malmö, Sweden
Correspondence: T Bjørge, Department of Pathology, The Norwegian Radium Hospital, N-0310 Oslo, Norway. E-mail: tone.bjorge@oslo.online.no
Received 14 February 2002; Revised 27 March 2002; Accepted 10 April 2002.
Abstract
Human papillomavirus has emerged as the leading infectious cause of cervical and other anogenital cancers. We have studied the relation between human papillomavirus infection and the subsequent risk of anal and perianal skin cancer. A case–cohort study within two large Nordic serum banks to which about 760 000 individuals had donated serum samples was performed. Subjects who developed anal and perianal skin cancer during follow up (median time of 10 years) were identified by registry linkage with the nationwide cancer registries in Finland and Norway. Twenty-eight cases and 1500 controls were analysed for the presence of IgG antibodies to HPV 16, 18, 33 or 73, and odds ratios of developing anal and perianal skin cancer were calculated. There was an increased risk of developing anal and perianal skin cancer among subjects seropositive for HPV 16 (OR=3.0; 95%CI=1.1–8.2) and HPV 18 (OR=4.4; 95%CI=1.1–17). The highest risks were seen for HPV 16 seropositive patients above the age of 45 years at serum sampling and for patients with a lag time of less than 10 years. This study provides prospective epidemiological evidence of an association between infection with HPV 16 and 18 and anal and perianal skin cancer.
Keywords:
human papillomavirus, anal cancer, epidemiology
